These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8442095)

  • 1. Protection against graft-versus-host disease by large doses of donor CD4+ T cells: a novel approach to bone marrow transplantation.
    Heath WR; Miller JF; Sprent J
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1222-4. PubMed ID: 8442095
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective inhibition of CD4 graft-versus-host activity in IL-2-treated mice.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1225-6. PubMed ID: 8442096
    [No Abstract]   [Full Text] [Related]  

  • 3. Peripheral tolerance specific for host minor histocompatibility antigens in acute GVHR-protected mice is associated with functional deletion of CD4+ but not CD8+ T cells and an active suppressive mechanism.
    Miconnet I; Bruley-Rosset M; Halle-Pannenko O
    Transplant Proc; 1993 Feb; 25(1 Pt 1):327-8. PubMed ID: 8438320
    [No Abstract]   [Full Text] [Related]  

  • 4. LF 08-0299 protects murine recipients of minor antigen disparate donor bone marrow from lethal graft-versus-host disease.
    Bruley-Rosset M; Churaqui E; Annat J; Dutartre P
    Transplant Proc; 1996 Dec; 28(6):3114-6. PubMed ID: 8962208
    [No Abstract]   [Full Text] [Related]  

  • 5. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological mechanisms governing tolerance to self-major histocompatibility complex antigens after bone marrow transplantation.
    Hess AD; Fischer AC; Horwitz LR; Bright EC; Hess JM
    Transplant Proc; 1995 Feb; 27(1):1370-3. PubMed ID: 7878915
    [No Abstract]   [Full Text] [Related]  

  • 8. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells.
    Tang W; Yang Y; Zhang F; Li YC; Zhou R; Wang JX; Zhu YN; Li XY; Yang YF; Zuo JP
    Int Immunopharmacol; 2005 Dec; 5(13-14):1904-13. PubMed ID: 16275625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose heparin inhibits acute graft versus host disease in mice.
    Naparstek E; Slavin S; Weiss L; Sidi H; Ohana M; Reich S; Vlodavsky I; Cohen IR; Naparstek Y
    Bone Marrow Transplant; 1993 Sep; 12(3):185-9. PubMed ID: 8241974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells.
    Liu YP; Li Z; Nador RG; Strober S
    Transplantation; 2008 Feb; 85(4):607-14. PubMed ID: 18347541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both class I and class II responsive T cell subsets can separately initiate lethal graft-versus-host disease in H-2-incompatible murine radiation chimeras.
    Carmody L; Atkinson K; Cooley M; Chapman G; Biggs J; McKenzie I
    Transplant Proc; 1987 Apr; 19(2):2876-8. PubMed ID: 3105125
    [No Abstract]   [Full Text] [Related]  

  • 15. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia.
    Trenado A; Charlotte F; Fisson S; Yagello M; Klatzmann D; Salomon BL; Cohen JL
    J Clin Invest; 2003 Dec; 112(11):1688-96. PubMed ID: 14660744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia.
    Champlin R; Jansen J; Ho W; Gajewski J; Nimer S; Lee K; Territo M; Winston D; Tricot G; Reichert T
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1695-6. PubMed ID: 1899162
    [No Abstract]   [Full Text] [Related]  

  • 18. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
    Aizawa S; Kamisaku H; Sado T
    Bone Marrow Transplant; 1995 Oct; 16(4):603-9. PubMed ID: 8528179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.